Epidemiologic, humanistic and economic burden of hepatocellular carcinoma in the USA: a systematic literature review

Aly, Abdalla; Ronnebaum, Sarah M.; Patel, Dipen; Doleh, Yunes; Benavente, Fernando

doi:10.2217/hep-2020-0024

Cited by 52 publications

(68 citation statements)

References 121 publications

(426 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Liver cancer stands at the fourth leading cause of cancer-related deaths globally, with approximately 850,000 new cases and 780,000 deaths occurred in 2018 [ 1 , 2 ]. Hepatocellular carcinoma (HCC) is characterized by easy metastasis and poor prognosis, accounting for about 80% of primary liver cancers [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

New Insights into the Role of miR-29a in Hepatocellular Carcinoma: Implications in Mechanisms and Theragnostics

Yang

Chang

et al. 2021

JPM

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) remains one of the most lethal human cancer globally. For advanced HCC, curable plan for advanced HCC is yet to be established, and the prognosis remains poor. The detail mechanisms underlying the progression of HCC tumorigenicity and the corruption of tumor microenvironment (TME) is complex and inconclusive. A growing body of studies demonstrate microRNAs (miRs) are important regulators in the tumorigenicity and TME development. Notably, mounting evidences indicate miR-29a play a crucial role in exerting hepatoprotective effect on various types of stress and involved in the progression of HCC, which elucidates their potential theragnostic implications. In this review, we reviewed the advanced insights into the detail mechanisms by which miR-29a dictates carcinogenesis, epigenetic program, and metabolic adaptation, and implicated in the sponging activity of competitive endogenous RNAs (ceRNA) and the TME components in the scenario of HCC. Furthermore, we highlighted its clinical significance in diagnosis and prognosis, as well as the emerging therapeutics centered on the activation of miR-29a.

show abstract

Section: Introductionmentioning

confidence: 99%

New Insights into the Role of miR-29a in Hepatocellular Carcinoma: Implications in Mechanisms and Theragnostics

Yang

Chang

et al. 2021

JPM

View full text Add to dashboard Cite

show abstract

“…Primary liver cancer accounts for the third most deadly type of malignant tumor globally and approximately 80% of the cases are hepatocellular carcinoma (HCC) [ 1 , 2 ]. To date, despite the availability of many different therapeutic interventions, such as surgical resection, liver transplantation, radiofrequency ablation, chemoembolization, and target therapy [ 3 ], the prognosis of HCC remains poor, with a five-year overall survival (OS) rate below 20% [ 1 ].…”

Section: Introductionmentioning

confidence: 99%

MIR29A Impedes Metastatic Behaviors in Hepatocellular Carcinoma via Targeting LOX, LOXL2, and VEGFA

Yang

Tsai

Chang

et al. 2021

IJMS

View full text Add to dashboard Cite

Primary liver cancer accounts for the third most deadly type of malignant tumor globally, and approximately 80% of the cases are hepatocellular carcinoma (HCC), which highly relies on the activity of hypoxia responsive pathways to bolster its metastatic behaviors. MicroRNA-29a (MIR29A) has been shown to exert a hepatoprotective effect on hepatocellular damage and liver fibrosis induced by cholestasis and diet stress, while its clinical and biological role on the activity hypoxia responsive genes including LOX, LOXL2, and VEGFA remains unclear. TCGA datasets were retrieved to confirm the differential expression and prognostic significance of all genes in the HCC and normal tissue. The Gene Expression Omnibus (GEO) dataset was used to corroborate the differential expression and diagnostic value of MIR29A. The bioinformatic identification were conducted to examine the interaction of MIR29A with LOX, LOXL2, and VEGFA. The suppressive activity of MIR29A on LOX, LOXL2, and VEGF was verified by qPCR, immunoblotting, and luciferase. The effect of overexpression of MIR29A-3p mimics in vitro on apoptosis markers (caspase-9, -3, and poly (ADP-ribose) polymerase (PARP)); cell viability and wound healing performance were examined using immunoblot and a WST-1 assay and a wound healing assay, respectively. The HCC tissue presented low expression of MIR29A, yet high expression of LOX, LOXL2, and VEGFA as compared to normal control. Serum MIR29A of HCC patients showed decreased levels as compared to that of normal control, with an area under curve (AUC) of 0.751 of a receiver operating characteristic (ROC) curve. Low expression of MIR29A and high expression of LOX, LOXL2, and VEGFA indicated poor overall survival (OS). MIR29A-3p was shown to target the 3′UTR of LOX, LOXL2, and VEGFA. Overexpression of MIR29A-3p mimic in HepG2 cells led to downregulated gene and protein expression levels of LOX, LOXL2, and VEGFA, wherein luciferase reporter assay confirmed that MIR29A-3p exerts the inhibitory activity via directly binding to the 3′UTR of LOX and VEGFA. Furthermore, overexpression of MIR29A-3p mimic induced the activity of caspase-9 and -3 and PARP, while it inhibited the cell viability and wound healing performance. Collectively, this study provides novel insight into a clinical-applicable panel consisting of MIR29, LOX, LOXL2, and VEGFA and demonstrates an anti-HCC effect of MIR29A via comprehensively suppressing the expression of LOX, LOXL2, and VEGFA, paving the way to a prospective theragnostic approach for HCC.

show abstract

“…Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer [1], accounting for 70-90% of liver cancer deaths worldwide [2,3]. Treatment is not curative for most patients, who often experience poor clinical outcomes, with approximately three-quarters of patients dying within five years of diagnosis [4]. Patients with HCC have worse health-related quality of life (HRQL) than people with chronic liver disease [5].…”

mentioning

confidence: 99%

“…Fan and colleagues suggest that compromised physical wellbeing may often be a consequence of treatment side effects. Pain is the main symptom reported by patients, with an increasing impact on HRQL as patients approach the end of life [4].…”

mentioning

confidence: 99%

Patient Preferences for Advanced Hepatocellular Carcinoma Treatment: A Multicountry Stated Preference Study

Sharma

Costentin

et al. 2021

Future Oncol.

View full text Add to dashboard Cite

The present study aimed to explore patient preferences for attributes of advanced hepatocellular carcinoma (HCC) treatments. A stated preference survey was completed by 150 patients with HCC living in Europe. Overall survival (OS) was the most important attribute, closely followed by risk of diarrhea and hypertension, and other adverse event (AE) risks. Patients were willing to trade OS to reduce AE risks. While less important than OS and AEs, patients also preferred shorter waiting times, and one-off administration of selective internal radiation therapy and oral tablets over intravenous infusions. Although patients placed the most value on extending OS, they were willing to forego OS to avoid risk of treatment-related AEs, to maintain their quality of life.

show abstract

Epidemiologic, humanistic and economic burden of hepatocellular carcinoma in the USA: a systematic literature review

Cited by 52 publications

References 121 publications

New Insights into the Role of miR-29a in Hepatocellular Carcinoma: Implications in Mechanisms and Theragnostics

New Insights into the Role of miR-29a in Hepatocellular Carcinoma: Implications in Mechanisms and Theragnostics

MIR29A Impedes Metastatic Behaviors in Hepatocellular Carcinoma via Targeting LOX, LOXL2, and VEGFA

Patient Preferences for Advanced Hepatocellular Carcinoma Treatment: A Multicountry Stated Preference Study

Contact Info

Product

Resources

About